close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Boehringer Ingelheim

< Previous 1 2 Next >
News headline image
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
From Boehringer Ingelheim
Via Business Wire
News headline image
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
From Boehringer Ingelheim
Via Business Wire
News headline image
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
From Boehringer Ingelheim
Via Business Wire
News headline image
Mental health focus makes Boehringer Ingelheim stand out as Global Top Employer 2023
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim announces appointments to Board of Managing Directors
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia
From Boehringer Ingelheim
Via Business Wire
News headline image
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
From Boehringer Ingelheim
Via Business Wire
News headline image
University of Tübingen and Boehringer Ingelheim Join Forces to Lead AI and Data Science R&D for New Medical Breakthroughs
From Boehringer Ingelheim
Via Business Wire
News headline image
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
From Boehringer Ingelheim
Via Business Wire
News headline image
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim signs Option to Acquire Trutino Biosciences
From Boehringer Ingelheim
Via Business Wire
News headline image
BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim launches RenuTend™: a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses
From Boehringer Ingelheim
Via Business Wire
News headline image
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
From Boehringer Ingelheim
Via Business Wire
News headline image
Award: Boehringer Ingelheim is Global Top Employer 2022
From Boehringer Ingelheim
Via Business Wire
News headline image
EUR 50 million for social businesses - Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major Depressive Disorder and Schizophrenia
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
From Boehringer Ingelheim
Via Business Wire
News headline image
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
From Boehringer Ingelheim
Via Business Wire
News headline image
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
From Boehringer Ingelheim
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.